Breast Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Lobular Carcinoma In Situ
IntroductionThe term lobular carcinoma in situ (LCIS) is misleading. This lesion is more appropriately termed lobular neoplasia. Strictly speaking, it is not known to be a premalignant lesion, but rather a marker that identifies women at an increased risk for subsequent development of invasive breast cancer. This risk remains elevated even beyond 2 decades, and most of the subsequent cancers are ductal rather than lobular. LCIS is usually multicentric and is frequently bilateral. In a large prospective series from the National Surgical Adjuvant Breast and Bowel Project with a 5-year follow-up of 182 women with LCIS managed with excisional biopsy alone, only eight women developed ipsilateral breast tumors (four of the tumors were invasive). In addition, three women developed contralateral breast tumors (two of the tumors were invasive). Treatment Option OverviewMost women with LCIS have disease that can be managed without additional local therapy after biopsy. No evidence is
Breast Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (05 / 31 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Changes were made to this summary to match those made to the health professional version.
Male Breast Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of male breast cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process in
Breast Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Breast Cancer Prevention
Avoiding risk factors and increasing protective factors may help prevent cancer.Avoiding cancer risk factors may help prevent certain cancers. Risk factors include smoking, being overweight, and not getting enough exercise. Increasing protective factors such as quitting smoking, eating a healthy diet, and exercising may also help prevent some cancers. Talk to your doctor or other health care professional about how you might lower your risk of cancer.NCI's Breast Cancer Risk Assessment Tool uses a woman's risk factors to estimate her risk for breast cancer during the next five years and up to age 90. This online tool is meant to be used by a health care provider. For more information on breast cancer risk, call 1-800-4-CANCER.The following risk factors may increase the risk of breast cancer:Estrogen (made in the body)Estrogen is a hormone made by the body. It helps the body develop and maintain female sex characteristics. Being exposed to estrogen over a long time may increase the risk
Male Breast Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Changes to This Summary (09 / 19 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.
Appendix of Randomized Controlled Trials
Health Insurance Plan, United States 1963 [1,2]Age at entry: 40 to 64 years.Randomization: Individual, but with significant imbalances in the distribution of women between assigned arms, as evidenced by menopausal status (P < .0001) and education (P = .05). Sample size: 30,000 to 31,092 in study group and 30,565 to 30,765 in control group. Consistency of reports: Variation in sample size reports. Intervention: Annual two-view mammography (MMG) and CBE for 3 years. Control: Usual care. Compliance: Nonattenders to first screening (35% of the screened population) were not reinvited.Contamination: Screening MMG was not available outside the trial, but frequency of CBE performance among control women is unknown.Cause of death attribution: Women who died of breast cancer that had been diagnosed before entry into the study were excluded from the comparison between the screening and control groups. However, these exclusions were determined differently
Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Breast Cancer Screening Modalities—Mammography
Mammography Description and BackgroundMammography utilizes ionizing radiation to image breast tissue. The examination is performed by compressing the breast firmly between two plates. Such compression spreads out overlapping tissues and reduces the amount of radiation needed to image the breast. For routine screening in the United States, examinations are taken in both mediolateral oblique and craniocaudal projections. Both views should include breast tissue from the nipple to the pectoral muscle. Radiation exposure is 4 to 24 mSv per standard two-view screening examination. Two-view examinations are associated with a lower recall rate than are single-view examinations because they eliminate concern about abnormalities due to superimposition of normal breast structures.Under the Mammography Quality Standards Act (MQSA) enacted by Congress in 1992, all U.S. facilities that perform mammography must be certified by the U.S. Food and Drug Administration (FDA) to ensure the
Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Description of the Evidence
BackgroundBreast cancer incidence and mortalityBreast cancer is the most common noncutaneous cancer in U.S. women, with an estimated 64,640 cases of in situ disease, 232,340 new cases of invasive disease, and 39,620 deaths expected in 2013. Thus, fewer than 1 of 6 women diagnosed with breast cancer die of the disease. By comparison, about 72,220 American women are estimated to die of lung cancer in 2013. Males account for 1% of breast cancer cases and breast cancer deaths (refer to the Special Populations section of this summary for more information).Widespread adoption of screening increases breast cancer incidence in a given population and changes the characteristics of cancers detected, with increased incidence of lower-risk cancers, premalignant lesions, and ductal carcinoma in situ (DCIS). (Refer to the Ductal Carcinoma In Situ section in the Breast Cancer Diagnosis and Pathology section of this summary for more information.) Ecologic studies from the United States  and
Male Breast Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Inflammatory Male Breast Cancer
In inflammatory breast cancer, cancer has spread to the skin of the breast and the breast looks red and swollen and feels warm. The redness and warmth occur because the cancer cells block the lymph vessels in the skin. The skin of the breast may also show the dimpled appearance called peau d'orange (like the skin of an orange). There may not be any lumps in the breast that can be felt. Inflammatory breast cancer may be stage IIIB, stage IIIC, or stage IV.
Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Mammography—Variables Associated with Accuracy
Patient CharacteristicsSeveral characteristics of women being screened that are associated with the accuracy of mammography include age, breast density, whether it is the first or subsequent exam, and time since last mammogram. Younger women have lower sensitivity and higher false-positive rates on screening mammography than do older women (refer to the Breast Cancer Surveillance Consortium performance measures by age for more information).For women of all ages, high breast density is associated with 10% to 29% lower sensitivity. High breast density is an inherent trait, which can be familial [2,3] but also may be affected by age, endogenous  and exogenous [5,6] hormones, selective estrogen receptor modulators such as tamoxifen, and diet. Hormone therapy is associated with increased breast density and is associated not only with lower sensitivity but also with an increased rate of interval cancers.The Million Women Study in the United Kingdom revealed